BRPI0512583A - composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psorìase de unha e de infecções - Google Patents

composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psorìase de unha e de infecções

Info

Publication number
BRPI0512583A
BRPI0512583A BRPI0512583-9A BRPI0512583A BRPI0512583A BR PI0512583 A BRPI0512583 A BR PI0512583A BR PI0512583 A BRPI0512583 A BR PI0512583A BR PI0512583 A BRPI0512583 A BR PI0512583A
Authority
BR
Brazil
Prior art keywords
compositions
onychomycosis
infections
animal
treating
Prior art date
Application number
BRPI0512583-9A
Other languages
English (en)
Inventor
Frederick Dechow
Original Assignee
Mediquest Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/960,516 external-priority patent/US7740875B2/en
Application filed by Mediquest Therapeutics Inc filed Critical Mediquest Therapeutics Inc
Publication of BRPI0512583A publication Critical patent/BRPI0512583A/pt
Publication of BRPI0512583B1 publication Critical patent/BRPI0512583B1/pt
Publication of BRPI0512583B8 publication Critical patent/BRPI0512583B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psoríase de unha e de infecções é provida uma composição adequada para a liberação local de agentes cosméticos e/ou farmacêuticos na pele que contêm pelo menos dois solventes orgânicos biocompatíveis, um lipídio polar, um surfactante, uréia e um espessante, em que os solventes orgânicos incluem um éster e um álcool diídrico e/ou polihídrico. Também são reveladas composições que ainda contêm um agente cosmético e/ou farmacêutico, junto com a preparação e uso das mesmas.
BRPI0512583A 2004-10-08 2005-10-11 composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psoríase de unha e de infecções BRPI0512583B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/960,516 US7740875B2 (en) 2004-10-08 2004-10-08 Organo-gel formulations for therapeutic applications
US11/066,485 US20060078579A1 (en) 2004-10-08 2005-02-28 Organo-gel formulations for therapeutic applications
US11/150,254 US20060078580A1 (en) 2004-10-08 2005-06-13 Organo-gel formulations for therapeutic applications
PCT/US2005/036064 WO2006042059A1 (en) 2004-10-08 2005-10-11 Organo-gel formulations for therapeutic applications

Publications (3)

Publication Number Publication Date
BRPI0512583A true BRPI0512583A (pt) 2008-03-25
BRPI0512583B1 BRPI0512583B1 (pt) 2018-12-26
BRPI0512583B8 BRPI0512583B8 (pt) 2021-05-25

Family

ID=36148664

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512583A BRPI0512583B8 (pt) 2004-10-08 2005-10-11 composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psoríase de unha e de infecções

Country Status (8)

Country Link
US (3) US20060078580A1 (pt)
EP (1) EP1796632A4 (pt)
JP (1) JP2008515911A (pt)
KR (1) KR20070072482A (pt)
AU (1) AU2005294216C1 (pt)
BR (1) BRPI0512583B8 (pt)
CA (1) CA2567575C (pt)
WO (1) WO2006042059A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502127A (ja) * 2002-07-24 2006-01-19 ビーエーエスエフ アクチェンゲゼルシャフト アスコルビン酸塩の懸濁液及び酸化防止剤としての使用
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
ES2288133B1 (es) * 2006-06-12 2008-09-16 Maria Cristina Fernandez Rodriguez Composicion topica para el tratamiento de la psoriasis.
EP2124878B1 (en) * 2007-02-05 2015-09-02 Biophile Corporation, Ltd Increased effectiveness of allylamine drug compounds
EP1958639A1 (en) * 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans for the treatment of nail inflammatory diseases
GB0720716D0 (en) * 2007-10-23 2007-12-05 York Pharma Plc Novel formulation
WO2009054992A1 (en) * 2007-10-25 2009-04-30 Ivrea Pharmaceuticals, Inc. Antimicrobial compositions comprising docusate
US20090191138A1 (en) * 2008-01-30 2009-07-30 Mediquest Therapeutics, Inc. Novel topical formulations for improving the appearance of nails
WO2010011650A1 (en) * 2008-07-21 2010-01-28 Imi International Medical Innovations (D/B/A Procris Pharmaceuticals) Stable water-based topical pharmaceutical creams and methods of making and using same
CA2731455A1 (en) * 2008-07-23 2010-01-28 Gregor Cevc Methods of administering topical antifungal formulations for the treatment of fungal infections
WO2010047831A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
AU2009313928B2 (en) * 2008-11-14 2015-07-09 Archer Daniels Midland Company Organogel compositions and processes for producing
WO2010090654A1 (en) * 2009-02-05 2010-08-12 Tdt, Ltd. Methods of reducing the proliferation and viability of microbial agents
JP5582467B2 (ja) * 2009-04-23 2014-09-03 学校法人日本大学 レシチンおよび尿素を主成分とする逆紐状ミセルから成るオイルゲル
US20100273834A1 (en) * 2009-04-25 2010-10-28 Reza Babapour Treatment of onychomycosis and related compositions including urea
WO2011079234A2 (en) * 2009-12-23 2011-06-30 Nuvo Research Inc. Highly permeating terbinafine formulation
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
MX339957B (es) * 2010-05-14 2016-06-20 Archer Daniels Midland Co Composiciones alimenticias que comprenden organogeles.
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
JP5989095B2 (ja) * 2011-05-03 2016-09-07 アポニア ラボラトリーズ インコーポレイテッド イブプロフェンの経皮組成物およびその使用方法
EP2714010B1 (en) 2011-05-25 2017-03-01 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
US9375388B2 (en) 2011-09-23 2016-06-28 Indian Institute Of Technology, Bombay Nanoparticle based cosmetic composition
ES2625538T3 (es) 2012-01-23 2017-07-19 Novaliq Gmbh Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
CN104619314B (zh) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
BR112015005008B1 (pt) 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
EP2957612B1 (en) 2013-02-13 2018-04-25 Kyushu University Gelatinizer and organogel
EP2815757A1 (en) * 2013-06-17 2014-12-24 Hestia Investments Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
WO2016144121A2 (ko) * 2015-03-12 2016-09-15 동아제약 주식회사 케라틴 조직의 진균감염증 치료를 위한 약제학적 조성물
KR101690765B1 (ko) * 2015-04-17 2016-12-28 동아제약 주식회사 항진균성 활성물질을 포함하는 경피 제제
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
CN113662929A (zh) 2015-09-30 2021-11-19 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
ES2819005T3 (es) 2016-12-23 2021-04-14 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
IL276888B2 (en) 2018-03-28 2024-12-01 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
EP3603650A1 (fr) 2018-08-01 2020-02-05 Edix O Sarl Compositions injectables et a duree d'action prolongee pour leur utilisation dans le traitement de maladies de l'ongle et/ou pour accelerer la croissance de l'ongle
CN112888443A (zh) 2018-08-01 2021-06-01 爱迪克斯-欧有限公司 用于其在治疗指或趾甲疾病中的使用和/或用于加速指或趾甲生长的具有延长的作用持续时间的可注射组合物
EP3856124A1 (en) 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
ES2950878T3 (es) 2018-09-27 2023-10-16 Dermaliq Therapeutics Inc Formulación de protección solar de uso tópico
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
US11813354B1 (en) * 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
AU2021300281A1 (en) * 2020-06-30 2023-02-02 Dermira, Inc. RORγt inhibitors and topical uses thereof

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883545A (en) * 1968-08-31 1975-05-13 Hoechst Ag Certain 1-hydroxy-2-pyridones
US4021573A (en) * 1974-04-22 1977-05-03 The Regents Of The University Of California Psoriasis treatment with retinoic acid analogs
US3957971A (en) * 1974-07-29 1976-05-18 Lever Brothers Company Moisturizing units and moisturizing compositions containing the same
US4036970A (en) * 1975-07-28 1977-07-19 Syntex (U.S.A.) Inc. Imidazol-1-yl propane derivatives
US5132459A (en) * 1979-08-22 1992-07-21 Sandoz Ltd. Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
CY1410A (en) * 1979-08-22 1988-04-22 Sandoz Ag Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
FR2502951B1 (fr) 1981-04-06 1985-12-06 Sandoz Sa Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
DE3225706C2 (de) * 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
US5030625A (en) * 1984-11-22 1991-07-09 Sandoz Ltd. Anti-fungal homopropargylamine compounds
DE3582060D1 (de) * 1984-11-22 1991-04-11 Sandoz Ag Homopropargylamine.
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4788061A (en) * 1985-07-05 1988-11-29 Shore Ronald N Extended occlusive treatment of skin disorders
US4764381A (en) * 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
DE3544983A1 (de) * 1985-12-19 1987-06-25 Hoechst Ag Antimykotisch wirksamer nagellack
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
US4751245A (en) * 1986-06-25 1988-06-14 E. R. Squibb & Sons, Inc. Antifungal derivatives of N-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same
US4782059A (en) 1986-09-29 1988-11-01 Merck & Co., Inc. Method of controlling mycotic infections and compositions therefor
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
GB8630721D0 (en) * 1986-12-23 1987-02-04 Unilever Plc Cosmetic compositions
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
DE3720147A1 (de) * 1987-06-16 1988-12-29 Hoechst Ag Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
CH681427A5 (pt) 1987-07-01 1993-03-31 Zambon Spa
US5045317A (en) * 1987-07-16 1991-09-03 The Regents Of The University Of California Enhancing the cutaneous penetration of pharmacologically active agents
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
US4920112A (en) * 1988-04-18 1990-04-24 Merck & Co., Inc. Fungicidal compositions and method
US5181914A (en) * 1988-08-22 1993-01-26 Zook Gerald P Medicating device for nails and adjacent tissue
FR2646603B1 (fr) 1989-05-03 1991-07-12 Oreal Composition nettoyante
US5219877A (en) * 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
JP3116364B2 (ja) * 1989-10-02 2000-12-11 萬有製薬株式会社 エンイン誘導体の製造法
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
EP0514435B1 (de) 1990-02-08 1993-10-06 A. Nattermann & Cie. GmbH Alkohol enthaltende wässrige gelartige phospholipidzusammensetzung, ihre verwendung und topische zubereitungen, die diese enthalten
US5741513A (en) * 1990-02-08 1998-04-21 A. Natterman & Cie. Gmbh Alcoholic aqueous gel-like phospholipid composition, its use and topical preparations containing it
GB9027433D0 (en) * 1990-12-18 1991-02-06 Merrell Dow Pharma Anti-herpes castanospermine esters
FR2673537B1 (fr) * 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
HU223343B1 (hu) * 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
US6005001A (en) * 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
JPH0739325B2 (ja) * 1991-06-24 1995-05-01 株式会社島津製作所 住居用防カビ剤
US5318960A (en) * 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
US5985860A (en) * 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
US5750141A (en) * 1993-04-08 1998-05-12 The University Of Queensland Administration of vaso-active agent and therapeutic agent
JP2545729B2 (ja) * 1993-05-11 1996-10-23 工業技術院長 メトトレキセート誘導体とピラン共重合体の高分子結合体及びその製造方法
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
DE4337945A1 (de) * 1993-11-06 1995-05-11 Labtec Gmbh Pflaster zur Behandlung von Nagelmykosen
US5514698A (en) * 1994-03-21 1996-05-07 Ortho Pharmaceutical Corporation Antifungal vaginal cream composition
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
JP3081766B2 (ja) * 1994-05-06 2000-08-28 東興薬品工業株式会社 角質貯留型抗真菌外用組成物
DK1051972T3 (da) * 1994-05-27 2008-01-28 Strakan Int Ltd Nitrogenoxiddonorsammensætning og fremgangsmåde til behandling af anale lidelser
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
RU2166512C2 (ru) * 1995-01-16 2001-05-10 Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн Конъюгаты терапевтического соединения с жирной кислотой
US5639740A (en) * 1995-03-10 1997-06-17 Crandall; Wilson Trafton Topical moisturizing composition and method
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
GB9509631D0 (en) * 1995-05-12 1995-07-05 Sandoz Ltd Antifungal combination
US5652256A (en) * 1995-06-06 1997-07-29 Knowles; W. Roy Topical composition for fungal treatment
CA2231769A1 (en) * 1995-09-14 1997-03-20 James L. Sorenson Composition and method for treating diseased nails
NZ280065A (en) * 1995-09-20 1998-04-27 Apotex Inc Preparation of n-alkyl-n-(1-naphthylmethyl)alk-2-en-4-ynylamine derivatives
US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US20040039030A1 (en) * 1996-09-27 2004-02-26 Hoechst Akeengesellschaft Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US5807957A (en) * 1996-12-23 1998-09-15 Macrochem Corporation Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
CA2294480C (en) * 1997-06-23 2008-05-20 Queen's University At Kingston Microdose therapy of female sexual dysfunction by no, co, and their donors
EP1001927A2 (en) * 1997-07-15 2000-05-24 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents
US5993790A (en) * 1997-08-04 1999-11-30 Pedinol Pharmacal Inc. Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections
US5935577A (en) * 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
DE69918087D1 (de) * 1998-04-17 2004-07-22 Bertek Pharm Inc Topische formulierungen zur behandlung von nagel pilzerkrankungen
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
US6159977A (en) * 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
EP1159261B1 (en) * 1999-02-05 2005-11-02 Oridigm Corporation Antizyme modulators and their use
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
SE0000303D0 (sv) * 2000-01-31 2000-01-31 Xylogen Ab Novel compounds
US6632843B1 (en) * 2000-02-01 2003-10-14 Mark Friedman Treatment of bruxism
DE10011081A1 (de) * 2000-03-09 2001-09-13 Aventis Pharma Gmbh Antiinfektive Wirkstoffkombinationen und ihre Verwendung zur topischen Behandlung von Pilzerkrankungen der Fuß- und Fingernägel
US6485740B1 (en) * 2000-03-14 2002-11-26 Yutoku Pharmaceutical Ind., Co., Ltd. Transdermal methotrexate preparations
IT1318425B1 (it) 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro Impiego del resveratrolo per il trattamento di eczema desquamativo,acne e psoriasi.
US6281239B1 (en) * 2000-04-12 2001-08-28 Bradley Pharmeaceuticals, Inc. Method of treating onychomycosis
MXPA03003511A (es) 2000-10-27 2004-05-04 Leo Pharma As Composicion topica que contiene al menos una vitamina d o un analogo de vitamina de y al menos un corticosteroide.
GEP20063828B (en) * 2001-02-01 2006-05-10 Biogen Inc Methods for Treating or Preventing Skin Disorders Using CD2-Binding Agents
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
JP4843169B2 (ja) * 2001-02-27 2011-12-21 株式会社Ａｄｅｋａ 殺菌洗浄剤組成物
CA2440389A1 (en) * 2001-03-09 2002-10-03 Ortho-Mcneil Pharmaceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
GB0108082D0 (en) * 2001-03-30 2001-05-23 Novartis Consumer Health Sa Topical composition
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030091540A1 (en) * 2001-10-16 2003-05-15 Nawaz Ahmad Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity
AU2002364893A1 (en) 2001-10-22 2003-06-17 University Of Mississippi Delivery of medicaments to the nail
US6673842B2 (en) * 2002-03-20 2004-01-06 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US6986896B2 (en) * 2002-03-20 2006-01-17 Bradley Pharmaceuticals, Inc. Method of treating fungal conditions of the skin
US6743417B2 (en) * 2002-04-22 2004-06-01 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis with urea and an antioxidant
US6846837B2 (en) * 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US8486426B2 (en) * 2002-07-29 2013-07-16 Kimberly-Clark Worldwide, Inc. Methods and compositions for treatment of dermal conditions
JP2004083439A (ja) * 2002-08-23 2004-03-18 Ss Pharmaceut Co Ltd 爪用抗真菌外用剤
US6914079B2 (en) * 2002-09-23 2005-07-05 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
US7135194B2 (en) * 2002-09-27 2006-11-14 Birnbaum Jay E Subunguicide, and method for treating onychomycosis
US7700076B2 (en) * 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
CA2513399A1 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications

Also Published As

Publication number Publication date
US20060110342A1 (en) 2006-05-25
EP1796632A4 (en) 2009-03-11
WO2006042059A1 (en) 2006-04-20
AU2005294216B2 (en) 2010-06-24
BRPI0512583B8 (pt) 2021-05-25
JP2008515911A (ja) 2008-05-15
AU2005294216A1 (en) 2006-04-20
BRPI0512583B1 (pt) 2018-12-26
KR20070072482A (ko) 2007-07-04
US20100305081A1 (en) 2010-12-02
US7776349B2 (en) 2010-08-17
AU2005294216C1 (en) 2011-02-24
US20060078580A1 (en) 2006-04-13
CA2567575A1 (en) 2006-04-20
CA2567575C (en) 2009-01-20
EP1796632A1 (en) 2007-06-20

Similar Documents

Publication Publication Date Title
BRPI0512583B8 (pt) composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psoríase de unha e de infecções
SG156624A1 (en) Organo-gel formulations for therapeutic applications
Oh et al. Peppermint oil promotes hair growth without toxic signs
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
BRPI0511235A (pt) preparado tópico e método para a administração transdérmica e localização de agentes terapêuticos
AR024516A1 (es) Compuestos bi-aromaticos analogos de la vitamina d, su utilizacion, composicion farmaceutica y composicion cosmetica que comprenden al menos uno de dichos compuestos y utilizacion de dicha composicion cosmetica.
BRPI0608249A2 (pt) formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
MX9702415A (es) Extractos de cocoa antineoplastica y metodos para elaborar y usar los mismos.
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
BRPI0414320A (pt) composição para tratamento da pele
SE8600501L (sv) Preparat for behandling av nagelsvamp och seborroiskt eksem
BRPI0417666A (pt) composição para tratamento oral ou pessoal, método para administrar um material funcional a um sujeito humano ou animal, e, processo para preparar uma composição para tratamento oral ou pessoal
BRPI0510806A (pt) formulação do tipo spot-on para a aplicação tópica localizada, utilização de um princìpio ativo e método tratamento cosmético da pele
TR200401603T4 (tr) D vitamini benzerleri
US12582744B2 (en) Dressings comprising platelet lysate
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
CY1109843T1 (el) Αναλογα της βιταμινης d
MX2021004123A (es) Formulaciones de lactonas macrociclicas, procedimientos para su preparacion y uso de las formulaciones en el tratamiento de patologias secundarias a parasitos oftalmicos.
DE602005015781D1 (de) Kosmetische Zusammensetzungen enthaltend konkave Partikel
ATE322878T1 (de) Biotin enthaltende galenische formulierung
BR112012024394A8 (pt) Método para depilação e kit depilatório
UY37497A (es) Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
BR0311170A (pt) Método para fornecer uma composição tópica base para uso na preparação de uma composição tópica cosmética, composição cosmética, composição essencialmente anidra, uso da mesma, e, kit de partes para a preparação de uma composição cosmética
BR112021025545A2 (pt) Formulações de penetração transdérmica
BRPI0518160A (pt) composições ácidas e compensadas paa cuidados com a pele compreendendo nicotinamida e um agente de absorção

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: MEDIQUEST THERAPEUTICS, INC (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 860140107607 DE 01/07/2014, E NECESSARIO APRESENTAR O DOCUMENTO DE CESSAO DEVIDAMENTE NOTARIZADO E COM A LEGALIZACAO CONSULAR, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25A Requested transfer of rights approved

Owner name: MQT HOLDINGS LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/12/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2800 DE 03-09-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.